Investigation of Decitabine Effects on HDAC۳ and HDAC۷ mRNA Expression in NALM-۶ and HL-۶۰ Cancer Cell Lines

Background: Decitabine is a potent anticancer hypomethylating agent and changes the gene expression through the gene's promoter demethylation and also independently from DNA demethylation. So, the present study was designed to distinguish whether Decitabine, in addition to inhibitory effects on DNA methyltransferase, can change HDAC۳ and HDAC۷ mRNA expression in NALM-۶ and HL-۶۰ cancer cell lines. Methods: HL-۶۰, NALM-۶, and normal cells were cultured, and the Decitabine treatment dose was obtained (۱ μM) through the MTT assay. Finally, HDAC۳ and HDAC۷ mRNA expression were measured by Real-Time PCR in HL-۶۰ and NALM-۶ cancerous cells before and after treatment. Furthermore, HDAC۳ and HDAC۷ mRNA expression in untreated HL-۶۰ and NALM-۶ cancerous cells were compared to normal cells.  Results: Our results revealed that the expression of HDAC۳ and HDAC۷ in HL-۶۰ and NALM-۶ cells increases as compared to normal cells. After treatment of HL-۶۰ and NALM-۶ cells with Decitabine, HDAC۳, and HDAC۷ mRNA expression were decreased significantly.  Conclusions: Our data confirmed that the effects of Decitabine are not limited to direct hypomethylation of DNMTs, but it can indirectly affect other epigenetic factors, such as HDACs activity, through converging pathways.

Keywords:

Decitabine , HDAC۳ , HDAC۷ , HL-۶۰ , NALM-۶.